UNSPSC 51383702: Aurothioglucose

This classification denotes an immunosuppressant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2P2V9Q0E78. European Medicines Agency schedules Aurothioglucose in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12965MIG. Aurothioglucose generally arises in the molecular formula C6H11AUO5S. The term 'aurothioglucose' is a U.S. Pharmacopeial Convention designation. As of Q4 2014, AUROTHIOGLUCOSE remains the US FDA Preferred Term for this commodity.

Aurothioglucose bears US NLM identifiers UMLS ID C0018033 and NCI Concept Code C87435. SMILES: [AU]SC1OC(C(O)C(O)C1O)CO.

UNSPSC 51383702 Aurothioglucose is a Commodity code, but the recent state and local opportunities posted under this code show no procurement activity for aurothioglucose itself. Instead, the tagged solicitations reflect pharmaceutical procurement at the state and regional cooperative-purchasing level, spanning naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. The mismatch between the code's nominal scope and the actual buying activity suggests either miscoding in the source data or a broadening of the code's application by issuing bodies to encompass pharmaceutical supply acquisition more generally. State and local buyers posting under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). The work being solicited ranges from direct procurement of specific pharmaceutical products with defined unit volumes and quarterly delivery schedules to strategic market-intelligence gathering on direct-to-manufacturer contracting models and large-scale generic pharmaceutical commodity supply through authorized wholesale distributors.

Recent activity concentrates in Florida and Texas, with multistate reach through MMCAP's cooperative purchasing vehicle. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, response deadline July 26, 2023) seeking 1,900 units of naloxone and 800 drug deactivation systems annually on a fixed-fee, two-year term with one-year renewal option; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) soliciting vendor capabilities for direct-to-manufacturer prescription program implementation with no formal award value disclosed; and MMCAP's RFP S1070000015802 (posted January 20, 2026, response deadline March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with contract effectiveness July 1, 2026, and evaluations weighted 75 percent on price competitiveness. Vendors pursuing this code should expect cGMP and DSCSA compliance certification, E-Verify confirmation, commercial insurance minimums (general liability ranging $2 million to $5 million depending on procurement type), and quarterly or ongoing delivery obligations to state or county facilities.